AR127730A1 - AMPK ACTIVATORS - Google Patents
AMPK ACTIVATORSInfo
- Publication number
- AR127730A1 AR127730A1 ARP220103197A ARP220103197A AR127730A1 AR 127730 A1 AR127730 A1 AR 127730A1 AR P220103197 A ARP220103197 A AR P220103197A AR P220103197 A ARP220103197 A AR P220103197A AR 127730 A1 AR127730 A1 AR 127730A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently selected
- halogen
- hydrogen
- optionally substituted
- Prior art date
Links
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 title abstract 5
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 title abstract 5
- 239000012190 activator Substances 0.000 title abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 9
- 150000002367 halogens Chemical class 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 7
- 125000001424 substituent group Chemical group 0.000 abstract 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 4
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000007149 gut brain axis pathway Effects 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 210000005027 intestinal barrier Anatomy 0.000 abstract 1
- 230000007358 intestinal barrier function Effects 0.000 abstract 1
- 239000004031 partial agonist Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000002483 superagonistic effect Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Esta divulgación está dirigida, al menos en parte, a los activadores de AMPK útiles para el tratamiento de afecciones o trastornos relacionados con AMPK. En algunas realizaciones, la afección o el trastorno están relacionados con el eje intestino-cerebro. En algunas realizaciones, la afección o el trastorno están relacionados con infección sistémica e inflamación a causa de una barrera intestinal permeable. En algunas realizaciones, los activadores de AMPK son compuestos restringidos al intestino. En algunas realizaciones, los activadores de AMPK son agonistas, súper agonistas, agonistas completos o agonistas parciales. Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable de este, caracterizado porque: X es -O- o -S-; Y es -N- o -CR⁶-; R¹, R², R³ y R⁴ se seleccionan cada uno independientemente, en cada aparición, de halógeno, hidroxilo, alquilo C₁₋₄, -CN y haloalquilo C₁₋₄; n se selecciona de 0, 1, 2, 3 y 4; o se selecciona de 0, 1, 2, 3 y 4; p se selecciona de 0, 1 y 2; q se selecciona de 0, 1, 2, 3 y 4; R⁵ se selecciona de hidrógeno y alquilo C₁₋₄; R⁶ se selecciona de hidrógeno, halógeno, alquilo C₁₋₄ y haloalquilo C₁₋₄; D se selecciona de -P(O)(OR¹¹)₂, -P(O)R¹¹(OR¹¹), -S(O)₂OH y -L-K; L se selecciona de ˡ-(C(R¹³)₂)ʳ-, ˡ-O(C(R¹³)₂)ʳ-, ˡ-N(R¹²)(C(R¹³)₂)ₛ-, ˡ-C(O)O-, ˡ-OC(O)-, ˡ-C(O)N(R¹²)-, ˡ-N(R¹²)C(O)-, ˡ-N(R¹²)S(O)₂-, ˡ-S(O)₂N(R¹²)-, heterocicloalquilo de 4 a 6 miembros y heteroarilo de 5 a 6 miembros, donde ˡ denota la conexión con K; r se selecciona de 1, 2 y 3; s se selecciona de 0, 1, 2 y 3; K se selecciona de (I) y (II): (I) alquilo C₁₋₁₀ o heteroalquilo C₁₋₁₀, cada uno de los cuales está sustituido opcionalmente con uno a seis sustituyentes independientemente seleccionados de: halógeno, -OR¹⁴, -SR¹⁴, -N(R¹⁴)₂, -N⁺(R¹⁵)₃, -C(O)R¹⁴, -C(O)OR¹⁴, -OC(O)R¹⁴, -OC(O)N(R¹⁴)₂, -C(O)N(R¹⁴)₂, -N(R¹⁴)C(O)R¹⁴, -N(R¹⁴)C(O)OR¹⁴, -N(R¹⁴)C(O)N(R¹⁴)₂, -N(R¹⁴)S(O)₂(R¹⁴), -S(O)R¹⁴, -S(O)₂R¹⁴, -S(O)₂N(R¹⁴)₂, =O, -CN, -P(O)(OR¹⁶)₂, -P(O)R¹⁶(OR¹⁶), -S(O)₂OH, carbociclo C₃₋₁₀ y heterociclo de 3 a 10 miembros, donde cada carbociclo C₃₋₁₀ y heterociclo de 3 a 10 miembros está sustituido opcionalmente con uno a seis sustituyentes seleccionados independientemente de halógeno, alquilo C₁₋₆, -OR¹⁴, =O y -S(O)₂OH; y (II) carbociclo C₃₋₁₀ y heterociclo de 3 a 10 miembros, cada uno de los cuales está opcionalmente sustituido con uno a seis sustituyentes independientemente seleccionados de halógeno, -OR¹⁴, -SR¹⁴, -N(R¹⁴)₂, -N⁺(R¹⁵)₃, -C(O)R¹⁴, -C(O)OR¹⁴, -OC(O)R¹⁴, -OC(O)N(R¹⁴)₂, -C(O)N(R¹⁴)₂, -N(R¹⁴)C(O)R¹⁴, -N(R¹⁴)C(O)OR¹⁴, -N(R¹⁴)C(O)N(R¹⁴)₂, -N(R¹⁴)S(O)₂(R¹⁴), -S(O)R¹⁴, -S(O)₂R¹⁴, -S(O)₂N(R¹⁴)₂, -P(O)(OR¹⁶)₂, -P(O)R¹⁶(OR¹⁶), -S(O)₂OH, =O, -CN, alquilo C₁₋₁₀ y heteroalquilo C₁₋₁₀, donde cada alquilo C₁₋₁₀ y heteroalquilo C₁₋₁₀ está sustituido opcionalmente con uno a seis sustituyentes seleccionados independientemente de halógeno, -OR¹⁴, -SR¹⁴, -N(R¹⁴)₂, -N⁺(R¹⁵)₃, -C(O)OR¹⁴, -P(O)(OR¹⁶)₂, -P(O)R¹⁶(OR¹⁶), -S(O)₂R¹⁶, -S(O)₂OH y =O; R¹¹ se selecciona independientemente, en cada aparición, de hidrógeno, alquilo C₁₋₄ y haloalquilo C₁₋₄; R¹² se selecciona independientemente, en cada aparición, de hidrógeno y alquilo C₁₋₄ opcionalmente sustituido con halógeno, -OH, -NH₂ y -C(O)N(H)₂; R¹³ se selecciona independientemente, en cada aparición, de hidrógeno, alquilo C₁₋₄, haloalquilo C₁₋₄ e hidroxialquilo C₁₋₄; R¹⁴ se selecciona independientemente, en cada aparición, de: hidrógeno; y alquilo C₁₋₁₀ y heteroalquilo C₁₋₁₀ opcionalmente sustituido con uno a seis sustituyentes independientemente seleccionado de halógeno, -OR²¹, -SR²¹, -N(R²¹)₂, -N⁺(R¹⁵)₃, -C(O)R²¹, -C(O)OR²¹, -OC(O)R²¹, -OC(O)N(R²¹)₂, -C(O)N(R²¹)₂, -N(R²¹)C(O)R²¹, -P(O)(OR¹⁶)₂, -P(O)R¹⁶(OR¹⁶), -S(O)₂OH, =O y -CN; y carbociclo C₃₋₁₀ y heterociclo de 3 a 10 miembros, donde cada carbociclo C₃₋₁₀ y heterociclo de 3 a 10 miembros está sustituido opcionalmente con uno a seis sustituyentes seleccionados independientemente de halógeno, alquilo C₁₋₆, -OR²¹, -N⁺(R¹⁵)₃, -S(O)R²¹, -P(O)(OR¹⁶)₂, -P(O)R¹⁶(OR¹⁶), -S(O)₂OH, -S(O)₂N(R²¹)₂, =O y -CN; R¹⁵ se seleccionan cada uno de alquilo C₁₋₄; R¹⁶ se selecciona independientemente, en cada aparición, de hidrógeno y alquilo C₁₋₆; R²¹ se selecciona independientemente, en cada aparición, de hidrógeno, alquilo C₁₋₆, haloalquilo C₁₋₆, hidroxialquilo C₁₋₆ y carbociclo C₃₋₆, donde el carbociclo C₃₋₆ está opcionalmente sustituido con uno a seis sustituyentes independientemente seleccionados de -OH, alquilo C₁₋₆, haloalquilo C₁₋₆, hidroxialquilo C₁₋₆ y =O.This disclosure is directed, at least in part, to AMPK activators useful for the treatment of AMPK-related conditions or disorders. In some embodiments, the condition or disorder is related to the gut-brain axis. In some embodiments, the condition or disorder is related to systemic infection and inflammation due to a leaky intestinal barrier. In some embodiments, AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists, super agonists, full agonists, or partial agonists. Claim 1: A compound of formula (1), or a pharmaceutically acceptable salt thereof, characterized in that: X is -O- or -S-; Y is -N- or -CR⁶-; R¹, R², R³ and R⁴ are each independently selected, at each occurrence, from halogen, hydroxyl, C₁₋₄ alkyl, -CN and C₁₋₄ haloalkyl; n is selected from 0, 1, 2, 3 and 4; or is selected from 0, 1, 2, 3 and 4; p is selected from 0, 1 and 2; q is selected from 0, 1, 2, 3 and 4; R⁵ is selected from hydrogen and C₁₋₄ alkyl; R⁶ is selected from hydrogen, halogen, C₁₋₄ alkyl and C₁₋₄ haloalkyl; D is selected from -P(O)(OR¹¹)₂, -P(O)R¹¹(OR¹¹), -S(O)₂OH and -L-K; L is selected from ˡ-(C(R¹³)₂)ʳ-, ˡ-O(C(R¹³)₂)ʳ-, ˡ-N(R¹²)(C(R¹³)₂)ₛ-, ˡ-C(O )O-, ˡ-OC(O)-, ˡ-C(O)N(R¹²)-, ˡ-N(R¹²)C(O)-, ˡ-N(R¹²)S(O)₂-, ˡ -S(O)₂N(R¹²)-, 4- to 6-membered heterocycloalkyl and 5- to 6-membered heteroaryl, where ˡ denotes the connection with K; r is selected from 1, 2 and 3; s is selected from 0, 1, 2 and 3; K is selected from (I) and (II): (I) C₁₋₁₀ alkyl or C₁₋₁₀ heteroalkyl, each of which is optionally substituted with one to six substituents independently selected from: halogen, -OR¹⁴, -SR¹⁴, -N(R¹⁴)₂, -N⁺(R¹⁵)₃, -C(O)R¹⁴, -C(O)OR¹⁴, -OC(O)R¹⁴, -OC(O)N(R¹⁴)₂, -C( O)N(R¹⁴)₂, -N(R¹⁴)C(O)R¹⁴, -N(R¹⁴)C(O)OR¹⁴, -N(R¹⁴)C(O)N(R¹⁴)₂, -N(R¹⁴) S(O)₂(R¹⁴), -S(O)R¹⁴, -S(O)₂R¹⁴, -S(O)₂N(R¹⁴)₂, =O, -CN, -P(O)(OR¹⁶)₂, -P(O)R¹⁶(OR¹⁶), -S(O)₂OH, C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle, where each C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle is optionally substituted with one to six substituents independently selected from halogen, C₁₋₆ alkyl, -OR¹⁴, =O and -S(O)₂OH; and (II) C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one to six substituents independently selected from halogen, -OR¹⁴, -SR¹⁴, -N(R¹⁴)₂, -N⁺ (R¹⁵)₃, -C(O)R¹⁴, -C(O)OR¹⁴, -OC(O)R¹⁴, -OC(O)N(R¹⁴)₂, -C(O)N(R¹⁴)₂, -N (R¹⁴)C(O)R¹⁴, -N(R¹⁴)C(O)OR¹⁴, -N(R¹⁴)C(O)N(R¹⁴)₂, -N(R¹⁴)S(O)₂(R¹⁴), - S(O)R¹⁴, -S(O)₂R¹⁴, -S(O)₂N(R¹⁴)₂, -P(O)(OR¹⁶)₂, -P(O)R¹⁶(OR¹⁶), -S(O)₂OH , =O, -CN, C₁₋₁₀ alkyl and C₁₋₁₀ heteroalkyl, where each C₁₋₁₀ alkyl and C₁₋₁₀ heteroalkyl is optionally substituted with one to six substituents independently selected from halogen, -OR¹⁴, -SR¹⁴, -N( R¹⁴)₂, -N⁺(R¹⁵)₃, -C(O)OR¹⁴, -P(O)(OR¹⁶)₂, -P(O)R¹⁶(OR¹⁶), -S(O)₂R¹⁶, -S(O )₂OH and =O; R¹¹ is independently selected, at each occurrence, from hydrogen, C₁₋₄ alkyl and C₁₋₄ haloalkyl; R¹² is independently selected, at each occurrence, from hydrogen and C₁₋₄ alkyl optionally substituted with halogen, -OH, -NH₂ and -C(O)N(H)₂; R¹³ is independently selected, at each occurrence, from hydrogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl and C₁₋₄ hydroxyalkyl; R¹⁴ is independently selected, at each occurrence, from: hydrogen; and C₁₋₁₀ alkyl and C₁₋₁₀ heteroalkyl optionally substituted with one to six substituents independently selected from halogen, -OR²¹, -SR²¹, -N(R²¹)₂, -N⁺(R¹⁵)₃, -C(O)R²¹, -C(O)OR²¹, -OC(O)R²¹, -OC(O)N(R²¹)₂, -C(O)N(R²¹)₂, -N(R²¹)C(O)R²¹, -P( O)(OR¹⁶)₂, -P(O)R¹⁶(OR¹⁶), -S(O)₂OH, =O and -CN; and C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle, wherein each C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle is optionally substituted with one to six substituents independently selected from halogen, C₁₋₆ alkyl, -OR²¹, -N⁺ (R¹⁵)₃, -S(O)R²¹, -P(O)(OR¹⁶)₂, -P(O)R¹⁶(OR¹⁶), -S(O)₂OH, -S(O)₂N(R²¹)₂, =O and -CN; R¹⁵ are each selected from C₁₋₄ alkyl; R¹⁶ is independently selected, at each occurrence, from hydrogen and C₁₋₆ alkyl; R²¹ is independently selected, at each occurrence, from hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl and C₃₋₆ carbocycle, where the C₃₋₆ carbocycle is optionally substituted with one to six substituents independently selected from - OH, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl and =O.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163282373P | 2021-11-23 | 2021-11-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127730A1 true AR127730A1 (en) | 2024-02-21 |
Family
ID=86540430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220103197A AR127730A1 (en) | 2021-11-23 | 2022-11-22 | AMPK ACTIVATORS |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR127730A1 (en) |
| TW (1) | TW202329944A (en) |
| WO (1) | WO2023097187A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3178994A1 (en) | 2020-05-19 | 2021-11-25 | Iyassu Sebhat | Ampk activators |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3924343A1 (en) * | 2008-09-26 | 2021-12-22 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| WO2012033149A1 (en) * | 2010-09-10 | 2012-03-15 | 塩野義製薬株式会社 | Hetero ring-fused imidazole derivative having ampk activating effect |
-
2022
- 2022-11-21 WO PCT/US2022/080260 patent/WO2023097187A1/en unknown
- 2022-11-21 TW TW111144377A patent/TW202329944A/en unknown
- 2022-11-22 AR ARP220103197A patent/AR127730A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202329944A (en) | 2023-08-01 |
| WO2023097187A1 (en) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR127730A1 (en) | AMPK ACTIVATORS | |
| AR112682A1 (en) | HERBICIDE COMPOUNDS | |
| AR090191A1 (en) | DERIVATIVES OF THE ALCANOIC PHENIL ACID AS GPR AGONISTS | |
| AR127731A1 (en) | AMPK ACTIVATORS | |
| AR119753A1 (en) | NON-PEPTIDE AGONISTS OF THE SOMATOSTATIN RECEPTOR TYPE 5 AND USES THEREOF | |
| AR116695A1 (en) | NEUROSTEROIDS AND THEIR METHODS OF USE | |
| AR123757A1 (en) | RAF KINASE INHIBITORS | |
| AR127500A1 (en) | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | |
| AR127505A1 (en) | IRAQ-4 DEGRADERS AND SYNTHESIS THEREOF | |
| AR127483A1 (en) | ANTIBACTERIAL COMPOUNDS | |
| AR121282A1 (en) | NAMPT MODULATORS | |
| AR116626A1 (en) | FATTY ACID SYNTHASE (FASN) INHIBITORS | |
| AR111496A1 (en) | DERIVATIVES OF QUINOLEINE TO INCREASE THE ACTIVITY OF THE CFTR | |
| AR124138A1 (en) | SUBSTITUTED (AZA)BENZOTHIAZOLYL-PYRAZOLE COMPOUNDS | |
| AR121592A1 (en) | INHIBITORS OF A KRAS MUTANT PROTEIN | |
| AR122711A1 (en) | HETEROCYCLIC COMPOUND AS INHIBITOR OF CASEIN KINASE 1d AND/OR KINASE 5 ACTIVIN RECEPTOR TYPE | |
| AR121493A1 (en) | COMPOUNDS FOR USE IN INFLAMMATORY CONDITIONS | |
| AR123933A1 (en) | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE SEROTONIN 5-HT₂A RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | |
| FR487842A (en) | Process for preparing thorium compounds | |
| FR505725A (en) | Detergent compound | |
| CH81280A (en) | Flood of clay | |
| FR482372A (en) | Process for preparing chlorobenzene | |
| AR103758A1 (en) | DERIVATIVES OF USEFUL REPLACED NUCLEOSIDS AS ANTINEOPLASTIC AGENTS | |
| FR499839A (en) | Seed drill | |
| FI6673A (en) | The method of application of organic compounds is sulphurated |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |